Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron's stock price has experienced fluctuations over the past six months. The stock is down 4.18% in the past six months and 36.97% over the past year. A significant event was the failure of itepekimab in a late-stage clinical trial, leading to a stock pullback in May. Recently, Q3 2025 revenues exceeded expectations, but EPS decreased by 22.9% compared to last year. Dupixent sales showed strong growth, and the company received new FDA approvals and positive CHMP opinions for several drugs. A quarterly dividend of $0.88 per share was announced.

Information directly detailing the demand seasonality for Regeneron Pharmaceuticals, Inc.'s products and services is not readily available. Product demand is typically driven by disease prevalence, treatment guidelines, market access, and competitive landscape rather than seasonal consumer purchasing patterns.

Regeneron Pharmaceuticals is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company addresses critical medical conditions across various therapeutic areas, leveraging technologies like VelociSuite to accelerate drug discovery. Key products include Eylea for ocular conditions, Dupixent for inflammatory and allergic conditions, Libtayo for oncology, Praluent for cholesterol lowering, Kevzara for rheumatoid arthritis, Evkeeza for homozygous familial hypercholesterolemia, Inmazeb for Ebola virus infection, Arcalyst for autoinflammatory conditions, Zaltrap for metastatic colorectal cancer, and REGEN-COV for COVID-19.

Regeneron Pharmaceuticals has a global presence, operating in the United States and the Rest of the World. The company has offices in 12 countries and conducts clinical trials in more than 50 countries. Office locations include cities across North America and Europe.

Regeneron's brand reputation has been influenced by both positive developments and setbacks in the past year. The company has maintained a generally positive analyst sentiment, with an average rating of "Moderate Buy". Recent positive events include securing new FDA approvals and receiving positive CHMP opinions. However, the unexpected failure of the itepekimab clinical trial in May was a notable negative event.

Institutional investors hold a significant portion of Regeneron Pharmaceuticals, Inc., with institutional ownership at 90.24%. Insider ownership stands at 1.89%.